tLNP

News

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.

News

Preparing for an influx of cell and gene therapy approvals

CapstanTx secures $165 million to deliver precise in vivo ce...

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo

News

United's PAH drug clears phase 3 trial, setting up filings

United Therapeutics will file ralinepag as a treatment for pulmonary arterial hypertension later this year, but can it compete in a crowded market?

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks